Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.47% | 29.39% | 34.17% | -62.65% | -112.64% |
| Total Depreciation and Amortization | 2.08% | 3.23% | 2.20% | -57.67% | 171.19% |
| Total Amortization of Deferred Charges | -1.71% | 2.63% | 1.79% | -- | -- |
| Total Other Non-Cash Items | 291.40% | -139.80% | -56.15% | 67.91% | -28.02% |
| Change in Net Operating Assets | -0.85% | 184.54% | -41.68% | 233.78% | 68.97% |
| Cash from Operations | 61.30% | -17.61% | -3.45% | -1.73% | -5,889.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.78% | 78.24% | 109.97% | -4,770.22% | 47.65% |
| Cash from Investing | -24.75% | 75.81% | 109.97% | -4,770.22% | 47.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 3,644.47% | 57.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -- | -- | -100.00% | 3,428.48% | 263.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 147.40% | 32.16% | -306.42% | 129.10% | -187.63% |